Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation.

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects.

Precision gene editing is crucial for treating genetic diseases, as it enables targeted correction of specific mutations.

An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 ...

Precision gene editing is crucial for treating genetic diseases, as it enables targeted correction of specific mutations. A ...

OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to ...

Enables streamlined stability testing and release of higher quality AAV-based gene therapy products. - Provides much needed European capacity for AAV characterization and release. ROCKVILLE ...

Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, has received GMP certification for Quality Control (QC ...

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe.

Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe. COLOGNE, Germany, June 10, 2025 /PRNewswire/ -- Cellex ...